Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eugene Chang

Foot and Ankle Surgery Anchorage, AK Medical Doctor

NPI 1225066095 CMS profile 1166791

3801 Lake Otis Pkwy, Suite 300, Anchorage, AK 99508

Open in the dashboard

General payments

$7,104

29 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eugene Chang of Anchorage, AK is reported in the CMS Open Payments database as having received $7,104 across 29 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 45th percentile of Foot and Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,257 7
2024 General $5,271 10
2023 General $286 5
2022 General $181 3
2020 General $19 1
2019 General $90 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eugene Chang
  • Foot and Ankle Surgery median
  • Middle half of Foot and Ankle Surgery
  • National median

In program year 2025, general payments to Eugene Chang were reported at $1,257. Among 650 Foot and Ankle Surgery profiles paid that year, the median was $1,183 and the middle half received between $267 and $6,309.

Show as a table
Year Eugene Chang Foot and Ankle Surgery median Middle half National median
2019 $90 $1,327 $279–$5,421 $163
2020 $19 $795 $121–$3,473 $114
2021 $0 $1,289 $201–$4,963 $132
2022 $181 $1,539 $270–$6,067 $149
2023 $286 $1,117 $257–$5,264 $160
2024 $5,271 $1,064 $235–$4,944 $164
2025 $1,257 $1,183 $267–$6,309 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genzyme Corporation $4,990 1 payment
  2. Exactech, Inc. $1,376 8 payments
  3. Stryker Corporation $211 2 payments
  4. Fusion Orthopedics USA, LLC $195 5 payments
  5. Ethicon US, LLC $102 2 payments
  6. Integra LifeSciences Corporation $57 1 payment
  7. Pacira Pharmaceuticals Incorporated $56 3 payments
  8. Avanos Medical $24 2 payments
  9. Bioventus LLC $22 1 payment
  10. Wright Medical Technology, Inc. $21 1 payment
  11. Other $50 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $4,990 1 payment
  2. Travel and Lodging $1,074 2 payments
  3. Food and Beverage $1,020 25 payments
  4. Gift $19 1 payment
Products named General payments · program years 2019–2025
  1. VANTAGE Orthopaedic $1,195 4 payments
  2. VANTAGE Orthopaedic $181 4 payments
  3. INFINITY ADAPTIS $110 1 payment
  4. STRATAFIX $102 2 payments
  5. AUGMENT INJECTABLE $101 1 payment
  6. ETHICON $68 1 payment
  7. INSTRUMENTS-ORTHOPEDIC $57 1 payment
  8. INSTRUMENTS-GENERAL SURGERY $57 1 payment
  9. INSTRUMENTS-PLASTIC AND RECONSTRUCTIVE $57 1 payment
  10. INSTRUMENTS-MICROSURGERY $57 1 payment
  11. Other $240 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 84 billing codes

Paid by Medicare

$115,870

Of which drugs: $116

Medicare patients

375

Average age 71

Services billed

1,142

257 women, 118 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 71%
High blood pressure 60%
Ischemic heart disease 21%
Osteoporosis 19%
Diabetes 17%
Depression 16%
Atrial fibrillation 15%
Chronic kidney disease 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 69 152 $110

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Exparel
  • Pacira Pharmaceuticals Incorporated $24
$24 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

29 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Foot and Ankle Surgery in Alaska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record